Woman who avoided sunlight to prevent tanning breaks bone while turning in bed
The case came to light after Dr. Long Shuang, an attending physician at the emergency department of XinDu Hospital of Traditional Chinese Medicine, shared details of the incident. According to Dr. Long, the woman had avoided sunlight since childhood, never wore short sleeves outdoors, and was meticulous about sun protection to maintain fair skin.
Also read: Scotsman travels on India's 'worst airline' and leaves pleasantly surprised. Watch
This extreme lifestyle eventually led to a critical deficiency in vitamin D, which plays a vital role in calcium absorption and maintaining bone strength. Medical tests upon her admission confirmed that the woman had developed severe osteoporosis, making her bones so fragile that even the slightest movement caused a fracture.
While it is not known whether her family ever raised concerns about her sun-avoidance habits, the injury served as a stark wake-up call to the hidden dangers of extreme sun protection.
The incident has reignited a national conversation around China's growing trend of aggressive sun shielding, particularly among women, reported the outlet. It is increasingly common to see people using wide-brimmed visors, long gloves, face masks, and UV-resistant clothing to guard against sun exposure.
This cultural shift has drawn criticism from health professionals. Jiang Xiaobing, Chief Orthopaedic Spine Surgeon at The Second Affiliated Hospital of Guangzhou Medical University, warned about the unintended consequences of such practices in an online video.
'It is now common to see people fully covered from head to toe for sun protection – this is indeed unhealthy. All the bones in our body regenerate every 10 years, but from age 30, we begin to lose bone mass at a rate of 0.5 to 1 per cent per year. Low calcium intake, lack of sun exposure, and vitamin D deficiency all hinder calcium absorption. A sedentary lifestyle, smoking, and excessive drinking also compromise bone health.'
'We need to ensure adequate calcium intake, exercise regularly, and limit smoking and drinking. For instance, no more than two cans of beer per day if the alcohol content is five per cent. Menopausal women, in particular, should be exceptionally cautious,' he advised.
Also read: 'You want Google output at $8,000 per year?': Indian techie lashes out at US clients, asks them to 'chill'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
PM Modi asks scientists to focus on R&D, secure patents for new drugs
Prime Minister Narendra Modi on Friday asked scientists and entrepreneurs to focus more on research and development (R&D) and secure patents for new drugs and medical technologies to ensure self-reliance in the pharmaceutical segment. Speaking from the Red Fort on the occasion of India's 79th Independence Day, PM Modi said that this move will ensure that India not only meets its own healthcare needs but also becomes a global hub of medical innovation. The call comes at a time when India has been lagging behind in terms of R&D spending, according to a Department of Pharmaceuticals (DoP) study paper on industry-academia linkages in the segment. It states that while a number of initiatives for industry-academic linkages in India have produced positive research results over the years, due to their sporadic nature, India's share of world researchers has remained at about 2 per cent, compared to 20 per cent in the US and China. 'An analysis of the share in R&D reveals that in India, the government contributes between 75 and 80 per cent, the private sector contributes 20 to 25 per cent, and universities contribute 3 per cent,' the paper added. In comparison, OECD countries see a 69 per cent contribution from private sector companies, followed by universities at 18 per cent, government contribution at 10 per cent, and non-profit organisations at 3 per cent. Commenting on the issues faced by the pharma industry, Kiran Mazumdar-Shaw, executive chairperson of Biocon and Biocon Biologics, told CNBC TV18 that the timeline to take a new molecule from the lab to the market is a very long process, making investments in research and innovation very risky. 'Unless we have very bold regulatory reforms that shorten this lab-to-market journey, we may not see the research investment needed for a country like India,' she added. Calling on the industry to demonstrate India's ability to lead in science, technology, and human welfare, PM Modi also urged the nation to achieve self-reliance in medicines and innovation, highlighting the country's strength as the pharmacy of the world. India currently has approximately 3,000 pharmaceutical businesses with over 10,500 manufacturing facilities, offering around 60,000 generic brands in 60 therapeutic categories. Many Indian pharmaceutical companies are now looking to jump on the generic bandwagon for off-patent molecules, while pressing on plans to develop a biosimilars pipeline post the Covid-19 pandemic. Pharma firms have gone on a generic spree after several blockbuster molecules used in diabetes medications, such as empagliflozin and dapagliflozin, went off patent in the last two years. Major blockbuster molecules that have seen several generic launches in this timeframe include empagliflozin and dapagliflozin, used in diabetes medications, which saw the prices of these drugs fall by 85 per cent in the Indian market. Similarly, companies such as Sun Pharma, Torrent, Lupin, Glenmark, and Dr Reddy's are also working on generic versions of weight loss drugs based on the blockbuster molecule semaglutide, which is expected to go off patent by March 2026. According to the DoP's study paper, more than 300 drug patents in different categories and geographies will be expiring every year during the patent cliff period of 2022 to 2032. 'The patent cliff will provide an opportunity for Indian generic companies to enter the US and other regulated markets and produce more affordable versions of those medications,' the paper added. PM flags obesity crisis in I-Day speech, calls for less oil intake PM Modi on Friday expressed concerns over obesity becoming a future crisis for India, asking people to cut down consumption of cooking oil by at least 10 per cent. India is currently projected to have the third-highest population of overweight or obese people globally, after the United States of America (USA) and China. Asking every family to take the concern seriously, the Prime Minister resolved that the country must protect itself from obesity. 'While many steps will have to be taken, I have made one small suggestion that every family should resolve that when cooking oil comes into the house, it should be 10 per cent less than usual, and its use should also be 10 per cent less. By doing so, we shall make our contribution towards winning the fight against obesity,' he stated from the ramparts of the Red Fort. According to the National Family Health Survey-5 (2019-21), 24 per cent of women and 23 per cent of men in India are overweight or obese, a sharp rise from 20.7 per cent and 18.6 per cent recorded in the NFHS-4 (2015-16), respectively. A recent Lancet study had also predicted that nearly one-third of the country's population, amounting to 218 million men and 231 million women, will be obese by 2050.
India Today
4 hours ago
- India Today
Foreign Medical Graduate Examination June 2025 result out, scorecards Aug 21
The National Board of Examinations in Medical Sciences (NBEMS) has announced the results of the Foreign Medical Graduate Examination (FMGE) June 2025 session on August 13. The results are now available on the official NBEMS portals, and can check their result status using their application and roll numbers. The published results are digitally signed and serve as an official notification of CONDUCT AND SCOREBOARD AVAILABILITYThe FMGE June 2025 examination took place on July 26, 2025. Alongside the result announcement, NBEMS confirmed that individual scorecards will be available for download from August 21, 2025. These scorecards will remain accessible for only six months from the date of NBEMS has clarified that the scorecard alone cannot be used to obtain registration from State Medical Councils (SMCs).Only the FMGE Pass Certificate, issued after an in-person identity and credential verification, will be accepted for this RESULTS AND VERIFICATIONThe results of five candidates have been withheld pending clarifications from the National Medical Commission or based on the outcome of the Exam Ethics Committee qualified candidates, NBEMS will distribute pass certificates in person after verifying identity and credentials. The schedule for certificate collection will be announced separately on the NBEMS prevent misuse, NBEMS has stated that SMCs will receive the results directly in a secure format. This will allow councils to verify pass certificates before granting board also stressed that eligibility checks will continue even after results are declared. If any ineligibility is detected at a later stage, the result and/or pass certificate will be TAKEAWAYS FOR CANDIDATESCheck results at NBEMS official websites using roll and application available from August 21, valid for download for six certificates require in-person sent directly to SMCs for independent will be reviewed even after results; violations can lead to FMGE is a qualifying exam for Indian citizens with foreign medical degrees to practice in India, making these updates crucial for aspiring practitioners.- Ends
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
PM Modi urges scientists to focus on R&D, secure patents for new drugs
Prime Minister Narendra Modi on Friday urged scientists and entrepreneurs to focus more on research and development (R&D) and secure patents for new drugs and medical technologies to ensure self-reliance in the pharmaceutical segment. Speaking from the Red Fort on the occasion of India's 79th Independence Day, Modi said this would enable the country not only to meet its own healthcare needs but also to emerge as a global hub of medical innovation. The call comes at a time when India has been lagging in R&D spending, according to a Department of Pharmaceuticals (DoP) study paper on industry–academia linkage in the segment. The paper states that while a number of initiatives for industry–academic linkages in India have produced positive research results over the years, their sporadic nature has kept India's share of world researchers at about 2 per cent, compared to 20 per cent in the United States and China. 'An analysis of the share in R&D reveals that in India, the government contributes between 75 and 80 per cent, the private sector 20 to 25 per cent, and universities 3 per cent,' the paper noted. In comparison, OECD countries see 69 per cent of R&D funding from private sector companies, followed by universities at 18 per cent, government at 10 per cent, and non-profit organisations at 3 per cent. Calling on industry to demonstrate India's ability to lead in science, technology, and human welfare, Modi also urged the nation to achieve self-reliance in medicines and innovation, highlighting the country's role as the pharmacy of the world. India currently has around 3,000 pharmaceutical businesses with over 10,500 manufacturing facilities, offering about 60,000 generic brands in 60 therapeutic categories. Many Indian pharmaceutical companies are now pursuing opportunities in generic production for off-patent molecules while building biosimilars pipelines after the Covid-19 pandemic. Pharma firms have stepped up generic launches after several blockbuster molecules used in diabetes medications, such as empagliflozin and dapagliflozin, went off patent in the past two years. Prices of these drugs have fallen by as much as 85 per cent in the Indian market. Similarly, companies such as Sun Pharma, Torrent, Lupin, Glenmark, and Dr Reddy's are working on generic versions of weight-loss drugs based on the blockbuster molecule semaglutide, which is expected to go off patent by March 2026. According to the DoP study paper, more than 300 drug patents across different categories and geographies are set to expire every year during the 'patent cliff' period from 2022 to 2032. 'The patent cliff will provide an opportunity for Indian generic companies to enter the US and other regulated markets and produce more affordable versions of those medications,' the paper added.
